Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus

• Main Authors: Nicolas Salvadori, Bo Fan, Waralee Teeyasoontranon, Nicole Ngo-Giang-Huong, Siriluk Phanomcheong, Anita Luvira, Achara Puangsombat, Arunrat Suwannarat, Ussanee Srirompotong, Chaiwat Putiyanun, Tim R. Cressey, Luc Decker, Woottichai Khamduang, Linda Harrison, Camlin Tierney, John A. Shepherd, Athena P. Kourtis, Marc Bulterys, George K. Siberry, Gonzague Jourdain
• Format: Journal
• Published: 2019
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068428450&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/65731
• Institution: Chiang Mai University

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [e-mail]. In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.